Adagio Therapeutics Inc


Adagio Therapeutics Inc

  • Price (USD)6.91
  • Today's Change-0.18 / -2.54%
  • Shares traded3.16m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jan 27 2022 19:47 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated--
  • Employees68.00
  • Location
    Adagio Therapeutics Inc1601 Trapelo Road, Suite 178WALTHAM 02451United StatesUSA
  • Phone+1 (603) 252-2274
  • Fax+1 (302) 655-5049
  • Websitehttps://adagiotx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Cross Country Healthcare, Inc.1.25bn59.04m681.03m1.45k11.293.069.930.54411.591.5933.835.872.85--5.33863,157.9013.49-1.3918.62-1.7922.5525.564.73-0.6747--15.990.3201--1.731.7477.54--14.33--
Edgewise Therapeutics Inc-100.00bn-100.00bn690.14m30.00--2.42----------5.79----------------------------0.00-------76.43------
Century Therapeutics Inc0.00-70.22m715.42m121.00--1.54-----8.14-
Viad Corp349.34m-129.83m747.30m1.70k--29.17--2.14-6.38-6.3517.077.710.362634.557.50205,856.80-12.50-4.02-16.30-6.10-23.864.42-34.48-3.531.25-4.060.645---68.11-17.53-2,431.59--12.41--
Ventyx Biosciences Inc0.00-84.23m776.08m23.00---------1.72-1.720.002.80------0.00-------------------201.430.00-------551.12------
Adagio Therapeutics Inc-100.00bn-100.00bn788.77m68.00--1.25----------5.69----------------------------0.00--------------
Pardes Biosciences Inc-100.00bn-100.00bn791.08m----1.61----------7.47----------------------------0.00--------------
Vanda Pharmaceuticals Inc.268.32m34.26m821.76m292.0024.331.6722.143.060.60630.60634.758.860.489823.217.72918,890.406.
QuinStreet Inc598.83m11.97m832.62m614.0071.322.7829.491.390.21520.215210.795.531.39--7.60975,286.602.797.713.7210.5811.9612.272.004.84--12.310.000.0017.9814.2130.12---0.9192--
Heidrick & Struggles International, Inc.883.47m65.63m841.06m1.68k13.152.609.530.9523.263.2644.2416.501.06--5.04565,238.607.901.4413.542.4995.6697.507.431.47----0.00101.82-13.262.80-180.45---14.922.90
GH Research PLC-100.00bn-100.00bn855.74m8.00--3.02----------5.45----------------------------0.00-------43.87------
Day One Biopharmaceuticals Inc0.00-183.08m857.72m42.00--2.88-----3.00-
Vaxxinity Inc-100.00bn-100.00bn885.75m75.00--------------0.7505----------------------------0.1033-------181.01------
Data as of Jan 27 2022. Currency figures normalised to Adagio Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

31.25%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 202116.55m14.87%
RA Capital Management LPas of 30 Sep 20215.34m4.80%
Redmile Group LLCas of 30 Sep 20213.25m2.92%
ArrowMark Colorado Holdings LLCas of 30 Sep 20212.77m2.49%
Federated Global Investment Management Corp.as of 30 Sep 20212.55m2.30%
The Vanguard Group, Inc.as of 30 Sep 20211.88m1.69%
BlackRock Fund Advisorsas of 30 Sep 20211.14m1.03%
Franklin Advisers, Inc.as of 30 Sep 2021500.01k0.45%
Fidelity Investments Canada ULCas of 30 Nov 2021416.95k0.38%
Geode Capital Management LLCas of 30 Sep 2021372.03k0.33%
More ▼
Data from 30 Sep 2021 - 30 Nov 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.